Company profile: Precede Bio
1.1 - Company Overview
Company description
- Provider of liquid biopsy and epigenomic profiling solutions that analyze circulating chromatin and the DNA methylome from 1 mL of plasma to evaluate gene and pathway activation. Offerings include blood-based diagnostic tests for precision use of cancer medicines as a minimally invasive alternative to tissue biopsies, an assay revealing disease biology and therapeutic targets for research and therapy selection, and a RUO platform for drug developers and academic researchers.
Products and services
- Liquid Biopsy Platform: A high-resolution platform that profiles circulating chromatin and the DNA methylome from 1mL of plasma, resolving activation status of genes and pathways for precision medicine insights
- Blood-Based Diagnostic Tests: Minimally invasive tests developed using the liquid biopsy platform to enable precision use of cancer medicines, offering an alternative to tissue biopsies for patient selection
- Epigenomic Profiling Assay: A research-grade assay that reveals disease biology and therapeutic targets from 1mL of plasma, applied in cancer research and therapy selection to guide treatment decisions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Precede Bio
Aquinox Pharmaceuticals
HQ: Canada
Website
- Description: Provider of small molecule therapeutics for cancer and inflammatory diseases, including AQX-MN100 and a SH2-containing inositol 5'-phosphatase inhibition program; and of online pharmacy services offering over 1,700 prescription and over-the-counter drugs and a wide range of generics (Sildenafil, Finasteride, Dapoxetine, Ivermectin) with delivery across the US.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aquinox Pharmaceuticals company profile →
Kudos Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development based on the science of DNA damage sensing, signaling, and repair to address medical needs in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kudos Pharmaceuticals company profile →
Fabrus
HQ: United States
Website
- Description: Provider of functional therapeutic monoclonal antibody discovery and development targeting challenging cell surface proteins, including GPCRs and ion channels, supported by a unique antibody discovery platform and multiple preclinical lead candidates against important cancer targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fabrus company profile →
Proxima Therapeutics
HQ: United States
Website
- Description: Provider of radiation delivery systems for treating solid cancerous tumors, with an initial focus on brain and breast cancer, including the GliaSite RTS for brain cancer and the MammoSite RTS for breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proxima Therapeutics company profile →
Molecular Templates
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for cancer and other serious diseases, leveraging a proprietary engineered toxin body (ETB) platform with unique mechanisms of action. Pipeline includes MT-6402 (PD-L1), MT-8421 (CTLA-4), and MT-0169 (CD38). Operates a multi-product cGMP manufacturing facility in Austin, TX to supply clinical trial materials for internal and partnered ETB programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Molecular Templates company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Precede Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Precede Bio
2.2 - Growth funds investing in similar companies to Precede Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Precede Bio
4.2 - Public trading comparable groups for Precede Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →